OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Not yet Hlye:

Oxford Biomedica PLC
07 February 2005



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN


Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')


Termination of discussions


On 19 January 2005 the Board of Oxford BioMedica announced that it had received
an approach from a third party regarding a potential merger, which may or may
not lead to an offer for the Company.


The Board of Oxford BioMedica announces that the discussions that followed this
unsolicited approach have terminated.


7 February 2005


Enquiries:


Oxford BioMedica plc Tel: +44 (0) 1865 783000
Professor Alan Kingsman, Chief Executive Officer

Rothschild Tel: +44 (0) 20 7280 5000
Dr. Lynn Drummond


N M Rothschild & Sons Limited ('Rothschild'), which is authorised and regulated
by the Financial Services Authority in the United Kingdom, acts for Oxford
BioMedica plc and no one else in relation to the contents of this announcement
and will not be responsible to anyone other than Oxford BioMedica plc for
providing the protections afforded to clients of Rothschild nor for providing
advice in relation to the contents of this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange

see this one free fall for a week or so. Some very good news is now required to get this one back on track.

It had better be good...this was NOT the way to treat their shareholders....very autocratic.So,do we all pile back in at 14.50???Can someone inform me as to how much of their research is based on animal experiments.Thanks.

Shame, but two things which are interesting and promising from recent events:- that OXB is prepared to talks about merges or take overs and possibly they think they are worth more than 27p a share. Although still in profit on my holding I think I will hold for future results Annual report 2/3/05 Prelims results 3/3/05.

Don't know what proportion of animal testing is used, but await testing on the human species with interest!

Check out their website, I think their experiments have been on terminally-ill patients most recently and usual arrangements (on humans) before that. The later tests are unusual in that the patients must be certified they have a limited life (presumably because they need an autopsy) so it is not easy to determine the before/after (effectiveness) for the treatment, but I understood their tests of about 2-years ago were above expectations.
Bid/Merger
I suspect it is not OXB that is willing to consider a deal; rather that it is a Listing requirement that talks proceede. AK may be mistreating his (retail) shareholders as suggested above, but I suspect he'd rather be doing a deal or setting-up another trial, than talking to suits.
Resaults/Update
There may be some good news with the results so I'm in two minds about selling out; as often happens the sp rises in the weeks before the news -and these days news seems to be somewhat leaky for all stocks in general.
I hold OXB at an average about this level and wonder if trying to trade my position isn't risk-taking - as I don't think the price will slip to silly levels (eg 12p); what say you?

Afternoon All!

Enjoyed a lovely break from work last week especially the Super Reds victory
at Highbury (snigger! snigger! tee hee hee tee).

Getting back to today not I'm not surprised to see that the bid/merger talks
have been terminated and the sp has tumbled down past my forecast last week of
21p. Glad I sold up over a week ago and have not been tempted to rush back in
as yet.Hopefully I can dive back in and catch the next rise or maybe not.

Think it will be iteresting to see end of day buying (not sure today or tomorrow)

OH //go on/////SELL/////GET THE PRICE WAY DOWN///////then I can buy at low prices which i like to do with ALL my buys//////so go on sell sell////

The sp is starting to claw back some of its earlier losses and I would not
be surprised to see this continue today and tommorrow. The shares look cheap
at the present level and I am tempted to buy. However, I will continue to
resist and hope the sp falls another 15%-20% before I invest any money.

Any comments welcome on where you feel the share price will be by the end of
this week.

Impossible to say - esp when you have Citywire saying "13:59 Mon 07 Feb - Partner talks continue, says Oxford Biomedica boss". W/o any indication of other companies taking an interest then my guess is that the sp will not move much (or perhaps decline slowly) until the next Trovax update.

Pachandl

Good to hear from you again. Not sure I agree with all your above comments
regarding the sp.

I reckon that sp in this stock will remain volatile over the next month and
the remainder of this week will see steep rises or dips in the sp.

I'm hoping that the sp will continue to drop this week to enable me to climb
back on aboard. Such is the volatility of OXB just 2 weeks ago I would have
jumped at the chance of purchasing OXB at 0.1975p however, now I'm willing to
wait to see if it drop further.

I hope my strategy pays off. Greed is Good!

From Times

********************
Oxford BioMedica

BIOTECH investors do not take kindly to disappointments, so there was a degree of inevitability in the 20 per cent share price fall that followed news that merger talks between Oxford BioMedica and an unnamed suitor have come to nought.



It is the hope of many a stale bull that suitors from America, fortified by the higher stock market ratings on offer on Wall Street, might try to line up pipeline-bolstering deals on this side of the Atlantic. A deal involving Oxford BioMedica would certainly have furthered the argument nicely, but it was not to be. It would appear that the companys secret admirer could not agree a price with the co-founders Alan and Susan Kingsman.

That may leave the bulls seeking another champion to further their cause, but it is not necessarily bad news for BioMedica. The management is clearly open to offers, but unwilling to compromise on price.

With more than 20 million in the bank, and a promising anti-cancer vaccine nearing the end of four phase II clinical trials, the management can afford to wait. Work is also under way on treatments to cure Parkinsons disease and retionopathy, a form of blindness. The shares, down 5p at 19p, are still about 10 per cent higher than their level before news of merger talks broke, reflecting perhaps the emergence of Boris Jordan, the Russian hedge fund manager, on the share register. As with any biotech stock, the risks are very high, but Biomedicas diverse portfolio at least improves the chances of reward. Buy.
***********************************

Thanks Fred.

1701 - it looks like The Times has scotched chances of getting in at a lower price for the present. Not complaining! Stay lucky.

This volatility is so useful for making money.

Whenever it goes up significantly I reduce my holding & when it goes back down again, I use that profit to increase it again but I always keep an increasing core holding.

I think this company will win big in the end, it is not dependent on just 1 drug.

Apple

I agree with your comments 100%. There is plenty of money to be made on this
stock this year on the dips and rises.

Just read the article in 'The Times' and the buy recommendation Grrrrrrrrrr)
looks like my strategy of waiting for further dips in the sp this week has not
materialised as yet Grrrrrrrrrr).

Well done! To all those who continued to hold or buy after yesterday's heavy
fall in the sp.

Pachandl-I may live to regret not buying back in yesterday. There again I
may not? Greed is good (sometimes) Grrrrrrrrrrrrr!

Not positive whether this was posted earlier - but at least it suggests that I was initially right when guessing at Vernalis being the possible suitor.

...

http://news.independent.co.uk/business/news/story.jsp?story=608909
Oxford BioMedica dips 20% as merger fails
By Stephen Foley
08 February 2005


Oxford Biomedica is to pursue several further informal bid talks after the biotech company said yesterday that merger negotiations with its first suitor had collapsed.

The negotiations that have just been broken off are believed to have been with the acquisitive biotech company Vernalis. Sources said the talks stalled over a number of issues, including valuation. It is also understood that there was no agreement over the ongoing role of the company's founders, the husband and wife duo Professors Alan and Susan Kingsman.

Vernalis is chaired by Peter Fellner, the former chairman of Celltech, with a mission to consolidate the fragmented UK biotech sector.

The talks proved a "useful distraction", according to Professor Alan Kingsman, the chief executive, and are understood to have flushed out other expressions of interest. He said: "There are lots of smaller and larger companies active in looking for mergers and acquisitions. It never surprises me to get a call saying, 'Alan, let's have a chat about getting the companies together'."

Share in the group plunged 20 per cent on news that merger talks with the as yet mystery suitor had been called off. They closed down 5p at 19.5p, still 10 per cent higher than when rumours of a possible deal began to swirl. Speculative investors had been betting on a takeover by one of OXB's giant drug development partners, although analysts said a tie-up with a UK quoted or private biotech company was more likely.

OXB was set up by the Kingsmans as a spin-out from Oxford University in 1995, and it specialises in developing drugs using gene therapy. Its most advanced product, TroVax, which is in the second of the three phases of human trials necessary for approval, is a treatment for cancer.

Professor Alan Kingsman said several elements of the proposed merger were unsatisfactory, but that he would not have stood in the way of a deal that was in shareholders' best interests. "I am not pathologically possessive of Oxford BioMedica, although I am totally committed to it. I have no plans to step aside and I don't particularly want to, but if it is important for shareholder value then I would step aside.

"As the products move into phase III and beyond and the emphasis becomes commercial rather than technical, then it may be time to step aside, but discussions with partners are now still significantly technical."

OXB is hopeful that phase II trials results on TroVax, due this month, will show that it prolongs the life of patients suffering from colorectal cancer.

If nothing else, all this speculation has finally got the company noticed, there are even suggestions that there may be several other co's eyeing oxb up, so it could get very interesting. Another chance to get in below 20p I did not expect. Trovax valuation is key here and with conservative estimates being 50p per share I am definitely in for the longer term or until takeover.

'Top ah da morning to ya all'

Splish!, Splash!, Splosh!

Dived back in this morning at 8.30am with a 150,000 buy at 22.75p and still
got more in the war chest if the sp dips again. Still annoyed at myself for
not getting back in at earlier levels on Monday (Grrrrrrrrrrr!)

I'm off down to boots now to stock up on some tablets for high blood
pressure and dodgy tickers. I reckon I'll need them while waiting for
the Trovax and company results.

Afternoon All!

Splish, Splash, Splosh!

Dipped into the war chest again this morning to buy 31,260 at slightly just
over 22p and will be adding to my holding if the sp continues to dip.

I expect the volatility to remain in the sp until the Trovax results this month
and preliminary results expected on 3/03/05.

1704 - totally agree with your analysis. The difficulty is in predicting whether the sp will move northwards simply because it appears OXB are now "in play".